Literature DB >> 33646395

APOL1 genotype-associated morphologic changes among patients with focal segmental glomerulosclerosis.

Jarcy Zee1, Michelle T McNulty2, Jeffrey B Hodgin3, Olga Zhdanova4, Sangeeta Hingorani5, Jonathan Ashley Jefferson6, Keisha L Gibson7, Howard Trachtman8, Alessia Fornoni9, Katherine M Dell10, Heather N Reich11, Serena Bagnasco12, Larry A Greenbaum13, Richard A Lafayette14, Debbie S Gipson15, Elizabeth Brown16, Matthias Kretzler17, Gerald Appel18, Kamalanathan K Sambandam19, Katherine R Tuttle20,21, Dhruti Chen7, Meredith A Atkinson22, Marie C Hogan23, Frederick J Kaskel24, Kevin E Meyers25, John O'Toole26, Tarak Srivastava27, Christine B Sethna28, Michelle A Hladunewich29, J J Lin30, Cynthia C Nast31, Vimal K Derebail7, Jiten Patel19, Suzanne Vento8, Lawrence B Holzman32, Ambarish M Athavale33, Sharon G Adler34, Kevin V Lemley35, John C Lieske23, Jonathan J Hogan32, Crystal A Gadegbeku36, Fernando C Fervenza23, Chia-Shi Wang13, Raed Bou Matar10,37, Pamela Singer28, Jeffrey B Kopp38, Laura Barisoni39, Matthew G Sampson40,41,42.   

Abstract

BACKGROUND: The G1 and G2 alleles of apolipoprotein L1 (APOL1) are common in the Black population and associated with increased risk of focal segmental glomerulosclerosis (FSGS). The molecular mechanisms linking APOL1 risk variants with FSGS are not clearly understood, and APOL1's natural absence in laboratory animals makes studying its pathobiology challenging.
METHODS: In a cohort of 90 Black patients with either FSGS or minimal change disease (MCD) enrolled in the Nephrotic Syndrome Study Network (58% pediatric onset), we used kidney biopsy traits as an intermediate outcome to help illuminate tissue-based consequences of APOL1 risk variants and expression. We tested associations between APOL1 risk alleles or glomerular APOL1 mRNA expression and 83 light- or electron-microscopy traits measuring structural and cellular kidney changes.
RESULTS: Under both recessive and dominant models in the FSGS patient subgroup (61%), APOL1 risk variants were significantly correlated (defined as FDR <0.1) with decreased global mesangial hypercellularity, decreased condensation of cytoskeleton, and increased tubular microcysts. No significant correlations were detected in MCD cohort. Independent of risk alleles, glomerular APOL1 expression in FSGS patients was not correlated with morphologic features.
CONCLUSIONS: While APOL1-associated FSGS is associated with two risk alleles, both one and two risk alleles are associated with cellular/tissue changes in this study of FSGS patients. Our lack of discovery of a large group of tissue differences in FSGS and no significant difference in MCD may be due to the lack of power but also supports investigating whether machine learning methods may more sensitively detect APOL1-associated changes.
© 2021. IPNA.

Entities:  

Keywords:  APOL1; Focal segmental glomerulosclerosis; Minimal change disease; Morphology; Pediatric

Mesh:

Substances:

Year:  2021        PMID: 33646395      PMCID: PMC8524347          DOI: 10.1007/s00467-021-04990-4

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  37 in total

1.  Association of trypanolytic ApoL1 variants with kidney disease in African Americans.

Authors:  Giulio Genovese; David J Friedman; Michael D Ross; Laurence Lecordier; Pierrick Uzureau; Barry I Freedman; Donald W Bowden; Carl D Langefeld; Taras K Oleksyk; Andrea L Uscinski Knob; Andrea J Bernhardy; Pamela J Hicks; George W Nelson; Benoit Vanhollebeke; Cheryl A Winkler; Jeffrey B Kopp; Etienne Pays; Martin R Pollak
Journal:  Science       Date:  2010-07-15       Impact factor: 47.728

2.  Transgenic expression of human APOL1 risk variants in podocytes induces kidney disease in mice.

Authors:  Pazit Beckerman; Jing Bi-Karchin; Ae Seo Deok Park; Chengxiang Qiu; Patrick D Dummer; Irfana Soomro; Carine M Boustany-Kari; Steven S Pullen; Jeffrey H Miner; Chien-An A Hu; Tibor Rohacs; Kazunori Inoue; Shuta Ishibe; Moin A Saleem; Matthew B Palmer; Ana Maria Cuervo; Jeffrey B Kopp; Katalin Susztak
Journal:  Nat Med       Date:  2017-02-20       Impact factor: 53.440

3.  Ultrastructural features and expression of cytoskeleton proteins of podocyte from patients with minimal change disease and focal segmental glomerulosclerosis.

Authors:  Su-Fang Shi; Su-Xia Wang; You-Kang Zhang; Ming-Hui Zhao; Wan-Zhong Zou
Journal:  Ren Fail       Date:  2008       Impact factor: 2.606

Review 4.  C1q nephropathy in the pediatric population: pathology and pathogenesis.

Authors:  Scott E Wenderfer; Rita D Swinford; Michael C Braun
Journal:  Pediatr Nephrol       Date:  2010-02-24       Impact factor: 3.714

5.  APOL1 localization in normal kidney and nondiabetic kidney disease.

Authors:  Sethu M Madhavan; John F O'Toole; Martha Konieczkowski; Santhi Ganesan; Leslie A Bruggeman; John R Sedor
Journal:  J Am Soc Nephrol       Date:  2011-10-13       Impact factor: 10.121

6.  Clinical Features and Histology of Apolipoprotein L1-Associated Nephropathy in the FSGS Clinical Trial.

Authors:  Jeffrey B Kopp; Cheryl A Winkler; Xiongce Zhao; Milena K Radeva; Jennifer J Gassman; Vivette D D'Agati; Cynthia C Nast; Changli Wei; Jochen Reiser; Lisa M Guay-Woodford; Martin R Pollak; Friedhelm Hildebrandt; Marva Moxey-Mims; Debbie S Gipson; Howard Trachtman; Aaron L Friedman; Frederick J Kaskel
Journal:  J Am Soc Nephrol       Date:  2015-01-08       Impact factor: 10.121

7.  APOL1 Renal-Risk Variants Induce Mitochondrial Dysfunction.

Authors:  Lijun Ma; Jeff W Chou; James A Snipes; Manish S Bharadwaj; Ann L Craddock; Dongmei Cheng; Allison Weckerle; Snezana Petrovic; Pamela J Hicks; Ashok K Hemal; Gregory A Hawkins; Lance D Miller; Anthony J A Molina; Carl D Langefeld; Mariana Murea; John S Parks; Barry I Freedman
Journal:  J Am Soc Nephrol       Date:  2016-11-07       Impact factor: 10.121

8.  Localization of APOL1 protein and mRNA in the human kidney: nondiseased tissue, primary cells, and immortalized cell lines.

Authors:  Lijun Ma; Gregory S Shelness; James A Snipes; Mariana Murea; Peter A Antinozzi; Dongmei Cheng; Moin A Saleem; Simon C Satchell; Bernhard Banas; Peter W Mathieson; Matthias Kretzler; Ashok K Hemal; Lawrence L Rudel; Snezana Petrovic; Allison Weckerle; Martin R Pollak; Michael D Ross; John S Parks; Barry I Freedman
Journal:  J Am Soc Nephrol       Date:  2014-07-10       Impact factor: 10.121

9.  APOL1 risk variants enhance podocyte necrosis through compromising lysosomal membrane permeability.

Authors:  Xiqian Lan; Aakash Jhaveri; Kang Cheng; Hongxiu Wen; Moin A Saleem; Peter W Mathieson; Joanna Mikulak; Sharon Aviram; Ashwani Malhotra; Karl Skorecki; Pravin C Singhal
Journal:  Am J Physiol Renal Physiol       Date:  2014-06-04

10.  Missense mutations in the APOL1 gene are highly associated with end stage kidney disease risk previously attributed to the MYH9 gene.

Authors:  Shay Tzur; Saharon Rosset; Revital Shemer; Guennady Yudkovsky; Sara Selig; Ayele Tarekegn; Endashaw Bekele; Neil Bradman; Walter G Wasser; Doron M Behar; Karl Skorecki
Journal:  Hum Genet       Date:  2010-07-16       Impact factor: 4.132

View more
  1 in total

Review 1.  The Roles of Fatty Acids and Apolipoproteins in the Kidneys.

Authors:  Xiaoyue Pan
Journal:  Metabolites       Date:  2022-05-20
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.